| Characteristic | Description |
|---|---|
| Generic Name | Tadalafil |
| Dosage Forms | Tablets: 5 mg, 10 mg, 20 mg |
| Pharmacokinetics | Absorption: Oral, Bioavailability: ~80% |
| Half-life | 17.5 hours |
| Metabolism | Hepatic, CYP3A4 |
| Excretion | Feces (61%), Urine (36%) |
| More Information | |
Pharmacokinetics
Tadalafil, the active component of Erectafil, demonstrates remarkable pharmacokinetic properties. Following oral ingestion, it achieves peak plasma concentrations in two hours. Its oral bioavailability stands impressively at approximately 80%, signifying effective systemic absorption. The drug exhibits a mean terminal half-life of 17.5 hours, enabling sustained therapeutic action over an extended duration.
Primarily metabolized in the liver, tadalafil undergoes transformation predominantly through the cytochrome P450 3A4 (CYP3A4) pathway. Hepatic metabolism converts it into active metabolites that contribute to its pharmacological effects. The excretion profile reveals 61% eliminated via feces and 36% through urine. This elimination balance ensures prolonged activity with minimal renal load.
Off-Label Uses
Erectafil, widely recognized for erectile dysfunction, finds usage beyond approved indications. It serves in the management of benign prostatic hyperplasia, alleviating symptoms and improving life quality. Its mechanism involves smooth muscle relaxation, increasing blood flow in the prostate and bladder.
Some clinicians prescribe tadalafil for pulmonary arterial hypertension. This off-label application arises from its ability to enhance exercise capacity through vasodilation of pulmonary vasculature. Though promising, such uses necessitate clinical supervision to ensure efficacy and safety.
Erectafil Precautions
Caution surrounds the use of Erectafil in specific populations. Patients with cardiovascular conditions must exercise vigilance due to potential cardiac risks. It is crucial to evaluate each patient’s cardiac function before initiating treatment.
Those with renal or hepatic impairment require adjusted dosages. Careful consideration avoids potential drug accumulation and toxicity. Awareness of individual health status ensures safe and effective therapy.
Cautions with Other Medicines
Interactions with concomitant medications can alter Erectafil’s efficacy and safety. The co-administration with nitrates is contraindicated due to the risk of severe hypotension. Patients should avoid combining it with other PDE5 inhibitors to prevent additive effects.
Moderate caution is necessary when using strong CYP3A4 inhibitors like ketoconazole. Such drugs increase tadalafil exposure, necessitating dose adjustments to minimize adverse effects. Concurrent use with antihypertensives warrants close monitoring.
Toxicity
Erectafil’s toxicity profile reveals potential adverse effects at high doses. Overdose can precipitate pronounced side effects, including severe headaches, dizziness, and hypotension. Prompt medical intervention is essential in overdose scenarios.
Monitoring for signs of allergic reactions remains crucial. Hypersensitivity may manifest as rashes or angioedema, demanding immediate discontinuation. Awareness and prompt response ensure patient safety.
Erectafil for Sale Online
The online availability of Erectafil offers convenience yet necessitates caution. Consumers should prioritize purchasing from reputable sources to avoid counterfeit products. Verification of authenticity and quality is paramount for safe use.
Healthcare professionals recommend consulting a doctor before initiating therapy. Online purchases should adhere to legal guidelines to prevent misuse and ensure patient welfare. Responsible purchasing supports therapeutic success and patient safety.
- Assess cardiovascular health prior to usage.
- Adjust dosage in renal or hepatic impairment.
- Avoid combination with nitrates and other PDE5 inhibitors.
- Consult healthcare providers before online purchases.